{"nctId":"NCT00496054","briefTitle":"Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)","startDateStruct":{"date":"2008-05"},"conditions":["Gastroenteritis","Rotavirus"],"count":110,"armGroups":[{"label":"RotaTeq™ Vaccine (V260)","type":"EXPERIMENTAL","interventionNames":["Biological: Rotavirus Vaccine, Live, Oral, Pentavalent"]}],"interventions":[{"name":"Rotavirus Vaccine, Live, Oral, Pentavalent","otherNames":["RotaTeq™ Vaccine","V260"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 6 weeks through exactly 12 weeks\n* Healthy infants\n\nExclusion Criteria:\n\n* Clinical evidence of active gastrointestinal illness\n* Fever, with a rectal temperature of greater than and equal to thirty eight degree celsius at the time of immunization\n* History of congenital abdominal disorders, intussusception, or abdominal surgery\n* History of known prior rotavirus disease\n* Known or suspected impairment of immunological function\n* Prior administration of any rotavirus vaccine\n* Known hypersensitivity to any component of the rotavirus vaccine, e.g. trypsin","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Participants Who Exhibit a 3 Fold Rise or Greater From Baseline to Approximately 6 Months in Rotavirus Specific Serum in IgA","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.35","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentage of Participants Who Exhibit a 3 Fold Rise or Greater From Baseline to Approximately 6 Months in Rotavirus Specific Serum in IgA","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.83","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G1 Serum Neutralizing Antibodies (SNA)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.24","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G2 Serum Neutralizing Antibodies(SNA)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.71","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G3 Serum Neutralizing Antibodies(SNA)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.39","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G4 Serum Neutralizing Antibodies(SNA)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.25","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in P1 Serum Neutralizing Antibodies(SNA)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.39","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G1 Serum Neutralizing Antibodies(SNA)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.37","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G2 Serum Neutralizing Antibodies(SNA)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.14","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G3 Serum Neutralizing Antibodies(SNA)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.29","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G4 Serum Neutralizing Antibodies(SNA)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.35","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in P1 Serum Neutralizing Antibodies(SNA)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.29","spread":null}]}]}]},{"type":"PRIMARY","title":"The Summary of Geometric Mean Titer (GMT) at Baseline & Approximately 6 Months for IgA","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.95","spread":null}]}]}]},{"type":"PRIMARY","title":"The Summary of Geometric Mean Titer (GMT) at Baseline & Approximately 6 Months for IgA","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.12","spread":null}]}]}]},{"type":"PRIMARY","title":"The Summary of Geometric Mean Titer (GMT) at Baseline & Approximately 6 Months for G1","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.79","spread":null}]}]}]},{"type":"PRIMARY","title":"The Summary of Geometric Mean Titer (GMT) at Baseline & Approximately 6 Months for G2","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.33","spread":null}]}]}]},{"type":"PRIMARY","title":"The Summary of Geometric Mean Titer (GMT) at Baseline & Approximately 6 Months for G3","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.32","spread":null}]}]}]},{"type":"PRIMARY","title":"The Summary of Geometric Mean Titer (GMT) at Baseline & Approximately 6 Months for G4","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.43","spread":null}]}]}]},{"type":"PRIMARY","title":"The Summary of Geometric Mean Titer (GMT) at Baseline & Approximately 6 Months for P1","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104.56","spread":null}]}]}]},{"type":"PRIMARY","title":"The Summary of Geometric Mean Titer (GMT) at Baseline & Approximately 6 Months for G1","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.19","spread":null}]}]}]},{"type":"PRIMARY","title":"The Summary of Geometric Mean Titer (GMT) at Baseline & Approximately 6 Months for G2","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.21","spread":null}]}]}]},{"type":"PRIMARY","title":"The Summary of Geometric Mean Titer (GMT) at Baseline & Approximately 6 Months for G3","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.95","spread":null}]}]}]},{"type":"PRIMARY","title":"The Summary of Geometric Mean Titer (GMT) at Baseline & Approximately 6 Months for G4","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.88","spread":null}]}]}]},{"type":"PRIMARY","title":"The Summary of Geometric Mean Titer (GMT) at Baseline & Approximately 6 Months for P1","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.01","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":104},"commonTop":["Diarrhoea","Vomiting","Pyrexia","Nasopharyngitis","Cough"]}}}